Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Saved in:
| Title: | Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. |
|---|---|
| Authors: | Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan., Ren Z; Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China., Guo Y; Nanfang Hospital, Guangzhou Southern Medical University, Guangzhou, China., Han G; Department of Liver Diseases and Digestive Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China., Lin H; Department of Tumor Interventional Radiology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, China., Zheng J; Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China., Ogasawara S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan., Kim JH; Department of Gastroenterology and Hepatology, Korea University Guro Hospital, Seoul, South Korea., Zhao H; Department of Liver Surgery, Peking Union Medical College Hospital, Dongcheng, Beijing, China., Li C; Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China., Madoff DC; Department of Radiology and Biomedical Imaging, Section of Interventional Radiology, Yale School of Medicine, New Haven, CT, USA., Ghobrial RM; Sherrie and Alan Conover Center for Liver Disease and Transplantation, J C Walter Jr Center for Transplantation, Houston Methodist Hospital, Houston, TX, USA., Kawaoka T; Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan., Gerolami R; Aix-Marseille Université, IRD, APHM, MEPHI, IHU Méditerranée Infection, Marseille, France; Assistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital de la Timone, Unité d'hépatologie, Marseille, France., Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan., Kumada H; Department of Hepatology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan., El-Khoueiry AB; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA., Vogel A; Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hanover, Germany; Department of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada., Peng X; Merck & Co, Inc, Rahway, NJ, USA., Mody K; Eisai, Nutley, NJ, USA., Dutcus C; Eisai, Nutley, NJ, USA., Dubrovsky L; Merck & Co, Inc, Rahway, NJ, USA., Siegel AB; Merck & Co, Inc, Rahway, NJ, USA., Finn RS; Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Llovet JM; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain. Electronic address: josep.llovet@mountsinai.org. |
| Corporate Authors: | LEAP-012 investigators |
| Source: | Lancet (London, England) [Lancet] 2025 Jan 18; Vol. 405 (10474), pp. 203-215. Date of Electronic Publication: 2025 Jan 08. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
